FDA Staff Push Back on HHS Plan to Loosen Peptide Drug Access

A contentious plan from the Department of Health and Human Services (HHS) aims to broaden access to unproven peptide drugs. This initiative met substantial resistance from Food and Drug Administration (FDA) scientific personnel, who expressed concerns.

The recently issued policy details a non-enforcement directive for specialty pharmacies selling injectable wellness peptides. These substances, including BPC-157 and TB-500, currently lack FDA approval for safety and efficacy.

Ordinarily, the FDA spearheads regulatory decisions concerning compounded drugs, making HHS’s lead on this policy exceptional. Earlier, the FDA had classified numerous peptides as unsuitable for compounding due to documented health risks.

HHS initially sought a formal FDA regulation to deem these peptides safe, but agency scientists firmly rejected the proposal. The department subsequently pivoted to a non-enforcement approach, largely circumventing direct FDA scientific endorsement.

The Health Secretary, an avowed proponent of peptides, advocated for their availability to counter unregulated “gray market” products. Consequently, the final policy incorporates FDA-suggested safeguards, mandating ingredient sourcing from registered facilities and adverse event reporting.